Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female outpatients aged 12 years or older at the time of signing the informed consent/assent form.
Patients who have been prescribed but not yet initiated treatment with tezepelumab according to the label and local market reimbursement criteria.
Diagnosis of asthma for at least 52 weeks prior to enrolment date and symptoms confirmed by the Investigator not to be due to alternative diagnoses.
Receipt of at least one prescription of high-dose Inhaled Corticosteroids (ICS) (according to the Global Initiative for Asthma 2024) during the 52 weeks prior to enrolment date.
Use of additional asthma maintenance controller medication(s) in addition to ICS either as free- or fixed-drug combination for at least 52 weeks prior to enrolment date.
Documented history of at least 1 asthma exacerbation during the 52 weeks prior to enrolment date.
Asthma Control Questionnaire (ACQ-6) score ≥1.5 (indicating inadequate asthma symptom control) at enrolment.
Availability of at least one Blood Eosinophil Count (BEC) measurement (in medical records) in the 52-week period prior to enrolment date.
Availability of participants' medical records for asthma exacerbations and unscheduled Health Care Resource Utilization (HCRU) for the 52 weeks prior to enrolment date.
Patients are able to understand and complete the Patient-Reported Outcome (PROs).
Provision of signed and dated written informed consent/assent (as applicable).
You may not be if
Any contraindication to tezepelumab as per the approved product label or in the opinion of the Investigator.
Concurrent or recent (\<30 days before the index date) treatment with biologics for asthma, with the exception of stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment).
Participation in an observational study that might, in the Investigator's opinion, influence the assessment for the current study, or participation in an interventional clinical trial in the last 3 months.
Currently pregnant (or intention to become pregnant) or lactating women.
Clareo Health | EVOLVE Study: The Real-life Clinical Practice With Tezepelumab in Greece
